| Serial Number | 90618201 |
| Word Mark | ANAKURIA |
| Filing Date | Thursday, April 1, 2021 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, March 18, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 20, 2023 |
| Name/Portrait Description and/or Consent Statement | The name(s), portrait(s), and/or signature(s) shown in the mark does not identify a particular living individual. |
| Goods and Services | Pharmaceutical preparations and substances for the prevention, treatment and diagnosis of cancer, diabetes, and heart disease; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of neurodegenerative diseases, namely, Alzheimer's disease, Parkinson's disease, and Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of immune disorders, namely, psoriasis, rheumatoid arthritis, lupus, Crohn's disease, inflammatory bowel disease, and multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of metabolic, endocrine, cardiovascular, oncological, gastrointestinal, musculoskeletal, nephrological, mitochondrial, autoimmune, and neurological related diseases and disorders; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of rare genetic diseases; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of Leigh's syndrome, Friedrich's ataxia, lymphangioleiomyomatosis (LAM) and tuberous sclerosis; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of obesity and obesity related diseases; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of age-related diseases; pharmaceutical preparations and substances for modulating the catabolic or anabolic response to nutrients; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of any disease related to muscle wasting diseases and conditions, including, cachexia, sarcopenia and muscle wasting due to prolonged immobilization; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting caloric intake and absorption; pharmaceuticals, therapeutics and nutraceuticals for use as active ingredients in foods, namely, dietary supplements; pharmaceuticals, therapeutics and nutraceuticals for use as food additives for medical purposes, namely, amino acids; dietetic substances for medical purposes, namely, dietetic foods such as dietary beverage supplements adapted for medical use; nutritional additives for medical purposes, namely, amino acids; pharmaceutical preparations and substances for the modulation of appetite, namely, appetite suppressants and satiety inducers |
| Goods and Services | Pharmaceutical research and development; drug development and discovery services; medical and scientific research; providing medical and scientific research information in the field of pharmaceuticals |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 9, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 9, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Anakuria Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02138 |
| Party Name | Anakuria Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02138 |
| Event Date | Event Description |
| Monday, March 18, 2024 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, March 18, 2024 | ABANDONMENT - NO USE STATEMENT FILED |
| Tuesday, August 15, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, June 20, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, June 20, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, May 31, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, May 15, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, November 14, 2022 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Tuesday, May 17, 2022 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Tuesday, May 17, 2022 | LETTER OF SUSPENSION E-MAILED |
| Tuesday, May 17, 2022 | SUSPENSION LETTER WRITTEN |
| Monday, May 16, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, May 16, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, May 16, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, November 16, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, November 16, 2021 | NON-FINAL ACTION E-MAILED |
| Tuesday, November 16, 2021 | NON-FINAL ACTION WRITTEN |
| Tuesday, November 16, 2021 | ASSIGNED TO EXAMINER |
| Friday, July 9, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, April 5, 2021 | NEW APPLICATION ENTERED |